Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 23:155:4252.
doi: 10.57187/s.4252.

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland

Martina Bertschinger  1 , Holger W Auner  2 , Veronika Ballova  3 , Carmen De Ramon Ortiz  4 , Christoph Driessen  5 , Sabine Gerull  6 , Dominik Heim  7 , Barbara Jeker  8 , Erika Lerch  9 , Rouven Müller  10 , Thomas Pabst  8 , Panagiotis Samaras  11 , Adrian Schmidt  12 , Christian Taverna  13 , Thilo Zander  14 , Ulrich Mey  15 , Christoph Renner  16
Affiliations
Free article
Review

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland

Martina Bertschinger et al. Swiss Med Wkly. .
Free article

Abstract

Multiple myeloma is a malignant disease characterised by the clonal proliferation of plasma cells. Since the last update of the Swiss recommendations for the diagnosis and treatment of multiple myeloma in 2019, the therapeutic landscape has evolved significantly, with the development of new monoclonal antibodies, novel combination therapies, and the introduction of T-cell-redirecting treatments such as bispecific antibodies and CAR T-cell therapy. This article summarises the current diagnostic procedures and therapeutic recommendations in Switzerland.

PubMed Disclaimer

References

    1. 1. Samaras, P., et al., Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly, 2019.149(1314):w20031. doi: https://doi.org/10.4414/smw.2019.20031
    1. 2. Bergsagel PL, Chesi MV. Molecular classification and risk stratification of myeloma. Hematol Oncol, 2013 Jun;31 Suppl 1(0 1):38-41. 10.1002/hon.2065
    1. 3. Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018 Oct;8(10):95. doi: https://doi.org/10.1038/s41408-018-0124-1
    1. 4. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: results of the IMAJEM Study. J Clin Oncol. 2017 Sep;35(25):2911–8. doi: https://doi.org/10.1200/JCO.2017.72.2975
    1. 5. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 Jun;127(24):2955–62. doi: https://doi.org/10.1182/blood-2016-01-631200

MeSH terms

Substances